Literature DB >> 32858076

Tumor microenvironment-responsive and oxygen self-sufficient oil droplet nanoparticles for enhanced photothermal/photodynamic combination therapy against hypoxic tumors.

Reesha Kv1, Te-I Liu1, I-Lin Lu2, Chia-Chen Liu1, Hsin-Hung Chen1, Ting-Yu Lu1, Wen-Hsuan Chiang3, Hsin-Cheng Chiu4.   

Abstract

The combination of photothermal and photodynamic therapy (PTT/PDT) shows pronounced potential as a prominent therapeutic strategy for tumor treatment. However, the efficacy is limited by insufficient tumor-targeted delivery of PTT and PDT reagents and the hypoxic nature of the tumor microenvironment. To overcome these limitations, tumor acidity-responsive lipid membrane-enclosed perfluorooctyl bromide oil droplet nanoparticles (NPs) surface modified with N-acetyl histidine-modified D-α-tocopheryl polyethylene glycol 1000 succinate (PFOB@IMHNPs) were developed, capable of co-delivering oxygen, IR780 (a photothermal agent) and mTHPC (a photodynamic sensitizer) into tumors. Through self-sufficient oxygen transportation in combination with promotion of cellular uptake upon acid-triggered generation of surface positive charge, the PFOB@IMHNPs effectively delivered IR780 and mTHPC and produced singlet oxygen within hypoxic TRAMP-C1 cells following exposure to irradiation at 660 nm. This led to effective killing of hypoxic cancer cells in vitro. Importantly, when irradiation at 808 and 660 nm was carried out, PT/PD combination therapy utilizing PFOB@IMHNPs dramatically suppressed the growth of TRAMP-C1 tumors through effective tumor-targeted cargo delivery and relief of tumor hypoxia. Our results suggest the high potential of the PFOB@IMHNPs developed in this study in clinical application for cancer treatment.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lipid-enclosed droplets; Photothermal/photodynamic combination therapy; Self-sufficient oxygen delivery; Tumor acidity responsive; Tumor hypoxia

Year:  2020        PMID: 32858076     DOI: 10.1016/j.jconrel.2020.08.038

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment.

Authors:  Shihui Bao; Hailun Zheng; Jinyao Ye; Huirong Huang; Bin Zhou; Qing Yao; Guangyong Lin; Hailin Zhang; Longfa Kou; Ruijie Chen
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

2.  BSA-encapsulated cyclometalated iridium complexes as nano-photosensitizers for photodynamic therapy of tumor cells.

Authors:  Yao Xu; Xiang Wang; Kang Song; Jun Du; Jinliang Liu; Yuqing Miao; Yuhao Li
Journal:  RSC Adv       Date:  2021-04-23       Impact factor: 3.361

3.  Dual-Depletion of Intratumoral Lactate and ATP with Radicals Generation for Cascade Metabolic-Chemodynamic Therapy.

Authors:  Feng Tian; Shiyao Wang; Keda Shi; Xingjian Zhong; Yutian Gu; Yadi Fan; Yu Zhang; Mo Yang
Journal:  Adv Sci (Weinh)       Date:  2021-10-29       Impact factor: 16.806

Review 4.  Nanotechnology-based combinatorial phototherapy for enhanced cancer treatment.

Authors:  Han Chen; Peter Timashev; Yuanyuan Zhang; Xiangdong Xue; Xing-Jie Liang
Journal:  RSC Adv       Date:  2022-04-04       Impact factor: 3.361

Review 5.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

Review 6.  Recent Advances in Strategies for Addressing Hypoxia in Tumor Photodynamic Therapy.

Authors:  Liang Hong; Jiangmin Li; Yali Luo; Tao Guo; Chenshuang Zhang; Sha Ou; Yaohang Long; Zuquan Hu
Journal:  Biomolecules       Date:  2022-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.